Physician profile
Kathleen Kerrigan
NPI 1457779035
$47,411.52
in general payments reported to CMS, 2019-2025
13 companies · $23K in 2025
The $23K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $146 · 2023: $21K · 2024: $2,735 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Consulting Fee: $4,377 · Travel and Lodging: $3,884 · Food and Beverage: $2,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,808.70 |
| Consulting Fee | $4,377.00 |
| Travel and Lodging | $3,883.57 |
| Food and Beverage | $2,195.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $35,332.71 | 2023-2025 | Tecentriq, Tecentriq Hybreza |
| Genzyme Corporation | $6,521.21 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $2,625.29 | 2023-2025 | Lynparza |
| Emd Serono, INC. | $1,762.00 | 2025 | |
| Beigene, Ltd. | $560.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $257.67 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $218.56 | 2023-2024 | Libtayo |
| Genentech, INC. | $54.27 | 2023 | Alecensa, Tecentriq |
| Myovant Sciences INC. | $21.31 | 2022 | |
| Astellas Pharma US INC | $20.19 | 2023 | |
| Merck Sharp & Dohme LLC | $19.54 | 2023 | Keytruda |
| Sumitomo Pharma America, INC. | $18.77 | 2023 | Orgovyx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Kerrigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.